AGC Biologics vs WuXi Biologics: CDMO Comparison

How does AGC Biologics compare to WuXi Biologics?

As of Oct 2026, AGC Biologics: 4 FDA inspections (including 1 NAI, 3 VAI and 0 OAI), 27 EMA/MHRA GMP certificates. Signal Score 79.9. WuXi Biologics: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 4 EMA/MHRA GMP certificates. Signal Score 82.7. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of AGC Biologics and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score
80/100
Quality (FDA + GMP)
100/100
FDA inspections
4
— NAI / VAI / OAI
1 / 3 / 0
FDA warning letters
0
EMA GMP certificates (active)
27
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
2
Capacity
Available
Modalities
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Shanghai, CN · Wuxi, CN
Signal Score
83/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
0 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
3
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
—
Modalities
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody

Key differences

  • AGC Biologics has more FDA inspections on record (4 vs 1) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • AGC Biologics has materially broader EMA GMP coverage (27 active certificates vs 3) — stronger EU footprint.
  • WuXi Biologics maintains 1 MHRA / UK GMP certificate; AGC Biologics does not.

Across the cross-modality scorecard, WuXi Biologics carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: AGC Biologics vs WuXi Biologics

How does AGC Biologics compare to WuXi Biologics?

On CDMO Signal's composite Signal Score, AGC Biologics is 80/100 and WuXi Biologics is 83/100; AGC Biologics has 4 FDA inspections on record vs 1 for WuXi Biologics; European coverage is 27 active EMA+MHRA certificates for AGC Biologics vs 4 for WuXi Biologics. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, AGC Biologics or WuXi Biologics?

Both AGC Biologics and WuXi Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. AGC Biologics has 4 FDA inspections on record; WuXi Biologics has 1.

How do AGC Biologics and WuXi Biologics compare on European GMP coverage?

AGC Biologics holds 27 active EMA GMP certificates and 0 MHRA / UK certificates. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — AGC Biologics or WuXi Biologics?

AGC Biologics is matched to 2 ClinicalTrials.gov records as a manufacturing partner; WuXi Biologics is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

What does the Signal Score gap mean in practice?

AGC Biologics carries a Signal Score of 80/100 and WuXi Biologics carries 83/100 — essentially tied for WuXi Biologics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating AGC Biologics and WuXi Biologics for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.